# 2026-23005: FDA May Downgrade Cancer Tests From Class III to II

2026-23005, Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2026-11-12, effective Either electronic or written comments on the proposed order must be submitted by January 11, 2027. Please see section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.; PRIA reads it as touching household money (as of 2026-11-13).

- Canonical: https://policyrisk.com/federal-register/2026-23005
- As of: 2026-11-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23005
- Title: Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 72825
- Published: 2026-11-12
- Effective: Either electronic or written comments on the proposed order must be submitted by January 11, 2027. Please see section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.
- Comments close: 2027-01-11
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-13

## In one line

FDA May Downgrade Cancer Tests From Class III to II

## Summary

The FDA wants to change the rules for certain cancer test systems called immunohistochemistry (IHC) tests. These tests will move from a strict, expensive approval process (Class III) to a simpler, faster one (Class II) with special safety rules. This change affects companies making these tests and could speed up getting them to doctors and patients. Comments on this plan are open until January 11, 2027.

## Abstract

The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is proposing minor revisions to an existing classification regulation and also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.

## Effects PRIA read

- IHC Oncology Tests Moved to Class II: benefit, medium. FDA proposes to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product from class III (premarket approval) to class II (special controls) subject to premarket notification (510(k)). The proposal explicitly lists product codes…
- 510(k) Required Before Marketing: cost, medium. If the proposed order is finalized, persons who intend to market these oncology therapeutic IHC-based test systems must submit a premarket notification under section 510(k) of the FD&C Act and receive clearance prior to marketing the device. FDA is not proposing to exempt this device type from 510(…
- Existing PMA Devices Keep Authorization: benefit, low. Oncology therapeutic IHC-based test systems that have prior PMA approval at the time of the final order may continue to be marketed under their existing PMA and would not require an additional marketing authorization. However, changes or modifications that could significantly affect safety or effec…
- May Speed Patient Access to Tests: benefit, medium. FDA states the reclassification to class II and use of the 510(k) pathway is less burdensome and generally results in a shorter premarket review timeline than a PMA, which FDA expects may provide more timely patient access and enable more manufacturers to develop these tests.
- Use of Predetermined Change Control Plans: benefit, low. FDA notes manufacturers may use predetermined change control plans (PCCPs) authorized by FDA to implement future modifications described in the PCCP without submitting a new 510(k) for each change, under section 515C of the FD&C Act as added by FDORA. FDA reviews a PCCP as part of a marketing submi…
- Devices Identified as Prescription IVDs: benefit, low. Under the proposed order, oncology therapeutic IHC-based test systems would be identified as prescription in vitro diagnostic (IVD) devices and would be subject to prescription labeling requirements for IVD products (see 21 CFR 809.10(a)(4) and (b)(5)(ii)).

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-23005 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with)
- [2026-23005 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-23005.pdf)

## Related
- [Previous: 2026-22944, Modification to Work Requirements for Able-Bodied Adults](https://policyrisk.com/federal-register/2026-22944)
- [Next: 2026-23017, Amendment of Jet Route J-21 in the Vicinity of Laredo, TX](https://policyrisk.com/federal-register/2026-23017)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23005 (as of 2026-11-13).
